Ozmosis and the Doctor's Channel Revolutionize Online Medical Knowledge Exchange With Vid...( nlaster@maloneyfox.com KNB Communic...),Health
Navigation Links
Ozmosis and the Doctor's Channel Revolutionize Online Medical Knowledge Exchange With Video Content
Date:4/21/2008
>nlaster@maloneyfox.com
Christopher Capot, for Ozmosis
KNB Communications
212-505-2441 office
203-379-8019 cell
'/>"/>
| SOURCE The Doctor's Channel Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Measuring medicine: How new technologies could help doctors predict patient outcomes
2. Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant
3. Cultural metamorphosis: Better doctors through better relationships
4. Doctors and Nurses Wellness Checklist: Healthy Diet, Exercise, Dietary Supplements
5. Majority of U.S. Doctors Back National Insurance Plan
6. TriWest Recognizes Contributions of TRICARE Docs to Military Community on Doctors Day
7. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
8. Doctors See How Cancer Drug Can Damage Kidneys
9. 3 new honorary doctors at Karolinska Institutet
10. Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS 08
11. Drugs, Doctors and Death: Heath Ledger Becomes Another Victim
Post Your Comments:
Breaking Medicine News(10 mins):Health News:When Parent Is Deployed, Kids Struggle 2Health News:When Parent Is Deployed, Kids Struggle 3Health News:Freudenberg-NOK CEO Accepts New Position 2Health News:Highmark Inc. Employees Earn $7,000 for Nonprofit Organizations 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 3Health News:Boies, Schiller & Flexner Commences Trial to Enforce Federal Medicaid Rights for Children 2
[0] When Parent Is Deployed, Kids Struggle[0] Freudenberg-NOK CEO Accepts New Position[0] Highmark Inc. Employees Earn $7,000 for Nonprofit Organizations[0] The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook[0] Boies, Schiller & Flexner Commences Trial to Enforce Federal Medicaid Rights for Children
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5MINDlink Foundation Launches to Connect the Cerebellum to Cures 61870 1MINDlink Foundation Launches to Connect the Cerebellum to Cures 61870 2Actuaries to Senate 3A Strengthen Individual Mandate 61868 1Actuaries to Senate 3A Strengthen Individual Mandate 61868 2Stop 26amp 3B Shop Alerts Customers to Voluntary Recall by Unilever 61866 1Stop 26amp 3B Shop Alerts Customers to Voluntary Recall by Unilever 61866 2
[0] Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing[0] VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation[0] The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
Other Medicine Technology:UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure 2UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure 3UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure 4CuraGen Announces Top-Line Phase II Results on Velafermin 2CuraGen Announces Top-Line Phase II Results on Velafermin 3CuraGen Announces Top-Line Phase II Results on Velafermin 4CuraGen Announces Top-Line Phase II Results on Velafermin 5CuraGen Announces Top-Line Phase II Results on Velafermin 6
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |